PE109599A1 - Formas de dosificacion farmaceuticas solidas - Google Patents

Formas de dosificacion farmaceuticas solidas

Info

Publication number
PE109599A1
PE109599A1 PE1998000752A PE00075298A PE109599A1 PE 109599 A1 PE109599 A1 PE 109599A1 PE 1998000752 A PE1998000752 A PE 1998000752A PE 00075298 A PE00075298 A PE 00075298A PE 109599 A1 PE109599 A1 PE 109599A1
Authority
PE
Peru
Prior art keywords
pharmaceutical dosage
dosage forms
solid pharmaceutical
soluble
water
Prior art date
Application number
PE1998000752A
Other languages
English (en)
Inventor
Isaac Ghebre-Sellassie
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE109599A1 publication Critical patent/PE109599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE REFRIERE A UNA FORMA DE DOSIFICACION FARMACEUTICA EN PARTICULAS SOLIDAS ADECUADAS PARA SUMINISTRO ORAL QUE COMPRENDE UN AGENTE FARMACEUTICO, COMO LA GLITAZONA, EN PARTICULAS, POBREMENTE SOLUBLE EN AGUA DISPERSADO EN UNA MATRIZ COMPUESTA POR UN POLIMERO SOLUBLE EN AGUA, EL CUAL PUEDE SER HIDROXIPROPIL CELULOSA; HIDROXIPROPIL METILCELULOSA Y POLIVINILPIRROLIDONA
PE1998000752A 1997-08-21 1998-08-20 Formas de dosificacion farmaceuticas solidas PE109599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21

Publications (1)

Publication Number Publication Date
PE109599A1 true PE109599A1 (es) 1999-12-19

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000752A PE109599A1 (es) 1997-08-21 1998-08-20 Formas de dosificacion farmaceuticas solidas

Country Status (17)

Country Link
US (1) US20010048946A1 (es)
EP (1) EP1011640A1 (es)
JP (1) JP2001515029A (es)
KR (1) KR20010023085A (es)
AR (1) AR018252A1 (es)
AU (1) AU8600098A (es)
BR (1) BR9811972A (es)
CA (1) CA2292586C (es)
CO (1) CO4960652A1 (es)
GT (1) GT199800136A (es)
HN (1) HN1998000115A (es)
NZ (1) NZ502869A (es)
PA (1) PA8458101A1 (es)
PE (1) PE109599A1 (es)
SV (1) SV1998000104A (es)
WO (1) WO1999008660A1 (es)
ZA (1) ZA987551B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
ES2096097T3 (es) * 1991-08-02 1997-03-01 Wilcom Tufting Pty Ltd Procedimiento y sistema de formacion de nudos.
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040013736A1 (en) * 2000-09-25 2004-01-22 Tomio Nakano Process for producing medicinal solid dispersion
EP1213014B1 (en) * 2000-12-07 2005-04-20 Warner-Lambert Company LLC Process and system for uniform release drug delivery
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
PL375345A1 (en) * 2002-08-12 2005-11-28 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
EP1648416A4 (en) * 2003-07-18 2012-03-28 Santarus Inc PHARMACEUTICAL FORMULATIONS FOR INHIBITING THE ACIDIC ACIDIFICATION AND MANUFACTURING AND USE METHOD
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP2007513145A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
KR101320408B1 (ko) * 2004-12-30 2013-10-30 피에르 파브르 메디카먼트 빈카 알카로이드 유도체의 안정한 고체분산체 및 제조방법
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
KR20080007357A (ko) * 2005-05-10 2008-01-18 노파르티스 아게 압축성이 열등한 치료학적 화합물을 갖는 조성물을제조하는 압출방법
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
AU2007335191A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
BRPI0913843A2 (pt) * 2008-07-03 2015-10-20 Novartis Ag processo de granulação por fusão
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
EP2675434A1 (en) 2011-02-17 2013-12-25 F.Hoffmann-La Roche Ag A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
RU2017121896A (ru) * 2011-09-14 2019-01-29 Селджин Корпорейшн Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
EP0580860B2 (en) * 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
US20010048946A1 (en) 2001-12-06
AR018252A1 (es) 2001-11-14
CA2292586A1 (en) 1999-02-25
KR20010023085A (ko) 2001-03-26
BR9811972A (pt) 2000-08-15
NZ502869A (en) 2002-10-25
CA2292586C (en) 2006-02-14
CO4960652A1 (es) 2000-09-25
JP2001515029A (ja) 2001-09-18
ZA987551B (en) 1999-02-23
EP1011640A1 (en) 2000-06-28
AU8600098A (en) 1999-03-08
PA8458101A1 (es) 2001-12-14
GT199800136A (es) 2000-02-11
SV1998000104A (es) 1999-07-02
WO1999008660A1 (en) 1999-02-25
HN1998000115A (es) 1999-06-02

Similar Documents

Publication Publication Date Title
PE109599A1 (es) Formas de dosificacion farmaceuticas solidas
CO5611097A2 (es) Tableta farmaceutica
AR027065A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
CU23440B7 (es) Composición de liberación sostenida de pramipexol
NO20004617L (no) Tablett som disintegrerer hurtig i munnhulen
CO5611096A2 (es) Forma de dosificacion farmaceutica para administracion mucosal
AR046811A1 (es) Formas de dosificacion oral de ziprasidona de liberacion sostenida
DE69726179D1 (de) Pharmazeutische suspensionssysteme
DE60316323D1 (de) Feste pharmazeutische formulierungen mit telmisartan
ATE251449T1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
ATE381926T2 (de) Vitaminzusammenstellung mit verzögerter freigabe
AU4989997A (en) Soluble form osmotic dose delivery system
BR0317103A (pt) Dispersões sólidas comprendendo um fármaco higroscópico e/ou deliquescente
JP2001515029A5 (es)
ATE328584T1 (de) In der mundhöhle schnell zerfallende orale feste verabreichungsform
UY28281A1 (es) Productos farmacéuticos
AR034517A1 (es) Formulacion farmaceutica
ATE311858T1 (de) Dosierungsform mit flüssiger formulierung
DE60102590D1 (de) Darreichungsformen zur behandlung von oralen mykosen
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
AR030497A1 (es) Suspension abrasiva fluida para usar en dentifricos
DE69927374D1 (de) Entzündungshemmende pharmazeutische formulierungen
ECSP034451A (es) Composicion de eletriptan en forma de particulas
CO5200833A1 (es) Regimenes de dosificacion para lasofoxifeno
RS50345B (sr) Vodena farmaceutska kompozicija koja sadrži ciklesonid

Legal Events

Date Code Title Description
FC Refusal